ATE388704T1 - Umkehrung der fortgeschrittenen glycosylierungsvernetzungen durch verwendung von heterozyklisch substituierten thiazoliumsalzen - Google Patents

Umkehrung der fortgeschrittenen glycosylierungsvernetzungen durch verwendung von heterozyklisch substituierten thiazoliumsalzen

Info

Publication number
ATE388704T1
ATE388704T1 AT99971712T AT99971712T ATE388704T1 AT E388704 T1 ATE388704 T1 AT E388704T1 AT 99971712 T AT99971712 T AT 99971712T AT 99971712 T AT99971712 T AT 99971712T AT E388704 T1 ATE388704 T1 AT E388704T1
Authority
AT
Austria
Prior art keywords
advanced glycosylation
reversal
heterocyclic substituted
aging
thiazolium salts
Prior art date
Application number
AT99971712T
Other languages
English (en)
Inventor
Dilip Wagle
Sheng Fang
Taikyn Rho
John Egan
Peter Ulrich
Anthony Cerami
Original Assignee
Synvista Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synvista Therapeutics Inc filed Critical Synvista Therapeutics Inc
Application granted granted Critical
Publication of ATE388704T1 publication Critical patent/ATE388704T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Catalysts (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT99971712T 1998-11-10 1999-11-10 Umkehrung der fortgeschrittenen glycosylierungsvernetzungen durch verwendung von heterozyklisch substituierten thiazoliumsalzen ATE388704T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/189,200 US6121300A (en) 1998-11-10 1998-11-10 Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts

Publications (1)

Publication Number Publication Date
ATE388704T1 true ATE388704T1 (de) 2008-03-15

Family

ID=22696355

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99971712T ATE388704T1 (de) 1998-11-10 1999-11-10 Umkehrung der fortgeschrittenen glycosylierungsvernetzungen durch verwendung von heterozyklisch substituierten thiazoliumsalzen

Country Status (11)

Country Link
US (4) US6121300A (de)
EP (1) EP1128830B1 (de)
JP (1) JP2002529414A (de)
KR (1) KR20010080969A (de)
AT (1) ATE388704T1 (de)
AU (1) AU767889B2 (de)
CA (1) CA2350211A1 (de)
DE (1) DE69938357D1 (de)
MX (1) MXPA01004721A (de)
NZ (1) NZ511569A (de)
WO (1) WO2000027395A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO315930B1 (no) 1995-01-18 2003-11-17 Picower Inst For Medical Res T Anvendelse av tiazoliumforbindelser ved fremstilling av farmasöytiske preparater, preparater som inneholder forbindelsene, samt nyetiazoliumforbindelser
US5656261A (en) 1995-01-18 1997-08-12 The Picower Institute For Medical Research Preventing and reversing advanced glycosylation endproducts
US6121300A (en) * 1998-11-10 2000-09-19 Wagle; Dilip R. Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts
US6458819B1 (en) * 2000-02-23 2002-10-01 Alteon, Inc. Thiazolium compounds and treatments of disorders associated with protein aging
MXPA03000386A (es) * 2000-07-13 2004-02-26 Alteon Inc Imidazolios y tiazolios substituidos con cianometilo y tratamientos de desordenes asociados con la maduracion de la proteina.
EP1313715B1 (de) * 2000-08-23 2007-08-01 Eli Lilly And Company Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten
WO2002053161A1 (en) * 2000-12-29 2002-07-11 Alteon, Inc. Method for treating fibrotic diseases or other indications
WO2002053101A2 (en) * 2000-12-29 2002-07-11 Alteon, Inc. Method for treating fibrotic diseases or other indications
MXPA03005954A (es) * 2000-12-29 2004-05-24 Alteon Inc Metodo para tratar enfermedades fibroticas u otras indicaciones iiic.
CA2433346A1 (en) * 2000-12-29 2002-07-11 John J. Egan Method for treating glaucoma ib
WO2002056836A2 (en) * 2001-01-22 2002-07-25 Farrington Pharmaceuticals, Llc Method and composition for rejuvenating hair, nails, tissues, cells and organs by ex-vivo or immersive treatment
US7022721B1 (en) * 2001-02-07 2006-04-04 Peter C Ulrich Method and composition for rejuvenating cells, tissues, organs, hair and nails
JP2004532862A (ja) * 2001-05-30 2004-10-28 アルテオン インコーポレイテッド 線維性疾患又は他の適応症の治療方法
CN1324019C (zh) * 2003-04-02 2007-07-04 深圳市东阳光实业发展有限公司 氮杂双环盐类化合物及其治疗蛋白老化疾病的用途
US20050014747A1 (en) * 2003-04-18 2005-01-20 Emily Reinhard Dihydrothiazine prodrugs of thiazolium agents
US20040265238A1 (en) 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
EP1753861A4 (de) * 2004-02-17 2010-03-10 Dynamis Therapeutics Inc Fructosamin-3-kinase und die bildung von kollagen und elastin
CN100560589C (zh) * 2004-04-21 2009-11-18 北京摩力克科技有限公司 咪唑并硒唑类化合物及其预防和/或者治疗与蛋白老化相关疾病的用途
CN1690057B (zh) * 2004-04-21 2010-05-26 北京摩力克科技有限公司 硒吩类衍生物及其预防和/或者治疗蛋白老化相关疾病的用途
WO2006032165A1 (en) * 2004-09-23 2006-03-30 Beijing Molecule Science And Technology Co., Ltd Novel substituted 5-membered-n-heterocyclic compounds and the use of them in treatment of the diseases associated with the aging of proteins
BRPI0707211A2 (pt) * 2006-01-23 2011-04-26 Procter & Gamble composições para tratamento na lavagem de roupas com corante de tiazólio
CN101007789B (zh) 2006-01-27 2014-08-20 北京摩力克科技有限公司 取代五元氮杂环盐类化合物及其治疗蛋白老化相关疾病的用途
FR2918570B1 (fr) * 2007-07-09 2012-10-05 Engelhard Lyon DIGLYCATION DES AGEs.
WO2009123753A1 (en) 2008-04-04 2009-10-08 North Carolina State University Inhibition of bacterial biofilms with imidazole-phenyl derivatives
WO2010144686A1 (en) 2009-06-10 2010-12-16 North Carolina State University Inhibition and dispersion of bacterial biofilms with benzimidazole derivatives
US9796952B2 (en) 2012-09-25 2017-10-24 The Procter & Gamble Company Laundry care compositions with thiazolium dye
WO2016179089A1 (en) 2015-05-01 2016-11-10 Rensselaer Polytechnic Institute Biomimetic nano-composite scaffold for enhanced bone healing and fracture repair
CN109431850A (zh) * 2018-03-16 2019-03-08 广东众尔健生物科技有限公司 一种鼠尾胶原在化妆品领域的应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5857116A (ja) * 1981-09-30 1983-04-05 Konishiroku Photo Ind Co Ltd マイクロプロセツサを塔載したカメラ
GB8300728D0 (en) * 1983-01-12 1983-02-16 Erba Farmitalia Substituted carboxy-thiazolo / 3 2 - a / pyrimidine derivatives
JPS60184038A (ja) * 1984-03-01 1985-09-19 Nippon Kasei Kk １−ヒドロキシ−２−オン類の製造方法
CA1273012A (en) * 1984-07-02 1990-08-21 Burton G. Christensen 1-methylcarbapenems having an externally alkylated mono- of bicyclic 2-quarternary heteroarylalkylthio substituent
CA1273011A (en) * 1984-07-02 1990-08-21 Susan M. Schmitt Carbapenems having an externally alkylated mono- or bicyclic 2-quaternary heteroarylalkylthio substituent
US4609670A (en) * 1984-11-13 1986-09-02 Eli Lilly And Company Imidazolium hypoglycemic agents
US4683312A (en) * 1984-11-13 1987-07-28 Eli Lilly And Company Imidazolium hypoglycemic agents
ZA86171B (en) 1985-01-16 1986-08-27 Hoffmann La Roche Polycyclic salts
US5219852A (en) * 1986-03-13 1993-06-15 Dr. Karl Thomae Gmbh Substituted thiazoles and oxazoles and pharmaceutical compositions and methods thereof
DE3621775A1 (de) * 1986-03-13 1988-01-07 Thomae Gmbh Dr K Neue substituierte thiazole und oxazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US4886814A (en) * 1986-03-13 1989-12-12 Dr. Karl Thomas Gmbh Substituted thiazoles and oxazoles and 2-hydroxy-morpholines
US5185334A (en) * 1989-07-31 1993-02-09 Schering Corporation 2,2-disubstituted glycerol and glycerol-like compounds, compositions and methods of use
JP2817219B2 (ja) * 1988-09-08 1998-10-30 武田薬品工業株式会社 カルバジン酸誘導体、その製造法及び製剤
DE3839758A1 (de) * 1988-10-24 1990-04-26 Bayer Ag Substituierte 2-aminothiazole
US5302608A (en) * 1988-11-18 1994-04-12 Takeda Chemical Industries, Ltd. Age formation inhibitors
US5128351A (en) * 1990-05-04 1992-07-07 American Cyanamid Company Bis-aryl amide and urea antagonists of platelet activating factor
US5225425A (en) * 1990-05-04 1993-07-06 American Cyanamid Company Bis-aryl amide antagonists of platelet activating factor
DE4124587A1 (de) * 1991-07-24 1993-01-28 Luitpold Werk Chem Pharm Dimethylacetessigsaeureamide, verfahren zu ihrer herstellung und arzneimittel
US5230998A (en) * 1991-07-25 1993-07-27 Neurath Alexander R Method for the prescreening of drugs targeted to the V3 hypervariable loop of the HIV-1 envelope glycoprotein gp 120
DE4129742A1 (de) * 1991-09-06 1993-03-11 Bayer Ag Heterocyclisch substituierte chinolylmethoxy-phenylacetamide
DE4218159C2 (de) * 1992-06-02 1997-07-31 Luitpold Pharma Gmbh 4,4,4-Trifluoracetessigsäureamide, Verfahren zu ihrer Herstellung und Arzneimittel
DE4222980A1 (de) * 1992-07-13 1994-01-20 Cassella Ag Verwendung von 2-(N-(2-Aminoethyl)amino)-essigsäure-derivaten
ES2096933T3 (es) * 1992-07-30 1997-03-16 Drug Delivery System Inst Ltd Compuesto capaz de permanecer en la region intracerebral y utilizacion del mismo.
TW268952B (de) * 1993-02-26 1996-01-21 Takeda Pharm Industry Co Ltd
JP3126541B2 (ja) * 1993-03-26 2001-01-22 千寿製薬株式会社 ベンゾチアゾール誘導体、その製法及びその用途
DE4341526A1 (de) * 1993-12-06 1995-06-08 Basf Ag 2,4-Diaminothiazole und ihre Herstellung
US5700819A (en) * 1994-11-29 1997-12-23 Grelan Pharmaceutical Co., Ltd. 2-substituted benzothiazole derivatives and prophylactic and therapeutic agents for the treatment of diabetic complications
EP1327887A3 (de) * 1995-01-18 2008-12-10 Synvista Therapeutics, Inc. Verwendung von Thiazoliumverbindungen zum Verhindern und Umkehren der Bildung von Endprodukten der fortgeschrittenen Glykosylierung
US5656261A (en) * 1995-01-18 1997-08-12 The Picower Institute For Medical Research Preventing and reversing advanced glycosylation endproducts
US5744451A (en) * 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US6121300A (en) * 1998-11-10 2000-09-19 Wagle; Dilip R. Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts

Also Published As

Publication number Publication date
US20020160992A1 (en) 2002-10-31
DE69938357D1 (de) 2008-04-24
EP1128830A1 (de) 2001-09-05
EP1128830A4 (de) 2004-03-31
CA2350211A1 (en) 2000-05-18
US6319934B1 (en) 2001-11-20
WO2000027395A1 (en) 2000-05-18
EP1128830B1 (de) 2008-03-12
AU767889B2 (en) 2003-11-27
US6790859B2 (en) 2004-09-14
KR20010080969A (ko) 2001-08-25
US6121300A (en) 2000-09-19
MXPA01004721A (es) 2002-09-18
AU1474800A (en) 2000-05-29
JP2002529414A (ja) 2002-09-10
NZ511569A (en) 2003-06-30
US20030176417A1 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
ATE388704T1 (de) Umkehrung der fortgeschrittenen glycosylierungsvernetzungen durch verwendung von heterozyklisch substituierten thiazoliumsalzen
ATE245420T1 (de) Verwendung von thiazoliumverbindungen zum verhindern und umkehren der bildung von endprodukten der fortgeschrittenen glykosylierung
ATE260099T1 (de) Neue hemmern von fortgeschrittenen glykosilierung-endprodukten
ATE361064T1 (de) Neue inhibitoren der bildung der fortgeschrittenen glykosylierungsendprodukte
EP0316852A3 (de) Hemmer von nichtenzymatischer Quervernetzung
DE3650080D1 (de) Verfahren und Mittel zur Hemmung des Proteinveraltens.
EA200500541A1 (ru) Состав со стабилизированными окислительно-восстановительными свойствами и способ стабилизации окислительно-восстановительных свойств
WO2004043481A3 (en) Compositions containing peptide copper complexes and metalloproteinase inhibitors, and methods related thereto
BR9206324A (pt) Composições para a conservação de madeira e materiais celulósicos,e,processo para o tratamento de um substrato de madeira ou outro material celulósico
DE60117605D1 (de) Thiazolyl-inhibitoren von tyrosinkinasen der tec-familie
DE60134769D1 (de) Zusammensetzung, die bakteriophagen enthält, zur behandlung von lebensmitteln zur verhinderung bakterieller kontamination
DE60316821D1 (de) Aminobenzothiazolverbindungen mit nos-hemmender wirkung
DE60004786D1 (de) Verfahren und zusammensetzung zur behandlung von akne
ATE178455T1 (de) Synergistische antimikrobielle zusammensetzung die methylen-bis-thiocyanat enthält
DE60043217D1 (de) Verwendung von stark absorbierenden polymeren für die behandlung von rohhäuten, zusammensetzungen und entsprechendes verfahren und so behandelte häute
DE69715218D1 (de) Substituierte imidazoliunsalze und deren verwendung zur hemmung der proteinalterung
DE602004005455D1 (de) Verfahren zur behandlung oder prävention von chronischen wunden und komplette nahrungszusammensetzung mit glycin und/oder leucin zur verwendung darin
US3352691A (en) Prevention of pink color in white onions
WO1996021450A3 (en) Bis-[hydrazones]
DK1175156T3 (da) Kornprodukt
NO170011C (no) Analogifremgangsmaate til fremstilling av propanolaminderivater
JPS5791908A (en) Cosmetic for skin
WO1997042175B1 (en) Substituted imidazolium salts and their use for the inhibition of protein ageing
EP1437053B1 (de) Fischfleischmehlprodukte auf basis von protease-haltigem fischfleisch
AU2425497A (en) 1,2,4-triazine derivatives for the inhibition of protein glycosylation

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties